Page 24 - GPD-4-3

Gene & Protein in Disease Targeting cathepsins during cancer development

97. Appelqvist H, Johansson AC, Linderoth E, et al. Lysosome- J Leukoc Biol. 2007;81(5):1213-1223.
mediated apoptosis is associated with cathepsin D-specific doi: 10.1189/jlb.0506359
processing of bid at Phe24, Trp48, and Phe183. Ann Clin Lab
Sci. 2012;42(3):231-242. 108. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of
Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S
98. Cirman T, Oresic K, Mazovec GD, et al. Selective disruption A. 2004;101(16):6164-6169.
of lysosomes in HeLa cells triggers apoptosis mediated by
cleavage of Bid by multiple papain-like lysosomal cathepsins. doi: 10.1073/pnas.0401471101
J Biol Chem. 2004;279(5):3578-3587. 109. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of
doi: 10.1074/jbc.M308347200 BIM-driven apoptosis in epithelial tumors and rational
chemotherapy. Cancer Cell. 2005;7(3):227-238.
99. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8
mediates the mitochondrial damage in the Fas pathway of doi: 10.1016/j.ccr.2005.02.008
apoptosis. Cell. 1998;94(4):491-501. 110. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-
doi: 10.1016/s0092-8674(00)81590-1 xL-Bak peptide complex: recognition between regulators of
apoptosis. Science. 1997;275(5302):983-986.
100. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a
Bcl2 interacting protein, mediates cytochrome c release doi: 10.1126/science.275.5302.983
from mitochondria in response to activation of cell surface 111. Lessene G, Czabotar PE, Colman PM. BCL-2 family
death receptors. Cell. 1998;94(4):481-490. antagonists for cancer therapy. Nat Rev Drug Discov.
doi: 10.1016/s0092-8674(00)81589-5 2008;7(12):989-1000.
101. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets doi: 10.1038/nrd2658
mitochondria and is required for cytochrome c release, 112. Wendt MD, Shen W, Kunzer A, et al. Discovery and structure-
while BCL-XL prevents this release but not tumor necrosis activity relationship of antagonists of B-cell lymphoma 2
factor-R1/Fas death. J Biol Chem. 1999;274(2):1156-1163. family proteins with chemopotentiation activity in vitro and
doi: 10.1074/jbc.274.2.1156 in vivo. J Med Chem. 2006;49(3):1165-1181.
102. Slee EA, Keogh SA, Martin SJ. Cleavage of BID during doi: 10.1021/jm050754u
cytotoxic drug and UV radiation-induced apoptosis occurs 113. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent
downstream of the point of Bcl-2 action and is catalyzed by and orally bioavailable Bcl-2 family inhibitor. Cancer Res.
caspase-3: A potential feedback loop for amplification of 2008;68(9):3421-3428.
apoptosis-associated mitochondrial cytochrome c release.
Cell Death Differ. 2000;7(6):556-565. doi: 10.1158/0008-5472.CAN-07-5836
114. Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax,
doi: 10.1038/sj.cdd.4400689
a targeted high-affinity inhibitor of BCL-2, in lymphoid
103. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces malignancies: A phase 1 dose-escalation study of safety,
the oligomerization and insertion of Bax into the outer pharmacokinetics, pharmacodynamics, and antitumour
mitochondrial membrane. Mol Cell Biol. 2000;20(3):929-935. activity. Lancet Oncol. 2010;11(12):1149-1159.
doi: 10.1128/MCB.20.3.929-935.2000 doi: 10.1016/S1470-2045(10)70261-8
104. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membrane- 115. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility
targeted death ligand, oligomerizes BAK to release of chronic lymphocytic leukemia to BCL2 inhibition: Results of a
cytochrome c. Genes Dev. 2000;14(16):2060-2071. phase I study of navitoclax in patients with relapsed or refractory
disease. J Clin Oncol. 2012;30(5):488-496.
105. Reiners JJ Jr., Caruso JA, Mathieu P, Chelladurai B, Yin XM,
Kessel D. Release of cytochrome c and activation of pro- doi: 10.1200/JCO.2011.34.7898
caspase-9 following lysosomal photodamage involves Bid 116. Rudin CM, Hann CL, Garon EB, et al. Phase II study of
cleavage. Cell Death Differ. 2002;9(9):934-944.
single-agent navitoclax (ABT-263) and biomarker correlates
doi: 10.1038/sj.cdd.4401048 in patients with relapsed small cell lung cancer. Clin Cancer
Res. 2012;18(11):3163-3169.
106. Stoka V, Turk B, Schendel SL, et al. Lysosomal protease
pathways to apoptosis. Cleavage of bid, not pro-caspases, is doi: 10.1158/1078-0432.CCR-11-3090
the most likely route. J Biol Chem. 2001;276(5):3149-3157.
117. Kipps TJ, Eradat H, Grosicki S, et al. A phase 2 study
doi: 10.1074/jbc.M008944200 of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-
263) with or without rituximab, in previously untreated
107. Blomgran R, Zheng L, Stendahl O. Cathepsin-cleaved Bid B-cell chronic lymphocytic leukemia. Leuk Lymphoma.
promotes apoptosis in human neutrophils via oxidative 2015;56(10):2826-2833.
stress-induced lysosomal membrane permeabilization.

Volume 4 Issue 3 (2025) 13 doi: 10.36922/gpd.4768